ALPHATEC HOLDINGS INC. Logo
US02081G2012
A2AP5V
ATEC

ALPHATEC HOLDINGS INC.

Loading quotes...

Forecast

The analysts' average price target is €13.94 (+79.87%). The median is €12.89 (+66.32%).

Buy
  17
Hold
  2
Sell
  1

  • Alphatec confirms growth model and full-year targets at Wells Fargo conference

    Alphatec said procedure volume was about 20% higher in the first half and reaffirmed its 2026 forecast of $882 million revenue, $140 million EBITDA and $20 million free cash flow. Management cited increasing surgeon adoption, EOS robotics, software and the Theradaptive acquisition as the main growth drivers, but acknowledged near-term pressure from lower revenue per procedure and reduced follow-up rates for biologics. For 2027 the company is targeting $1 billion in revenue, roughly 18% EBITDA margin and $65 million free cash flow, and sees further upside from margin improvements. Alphatec expects rising surgeon acceptance and product penetration to support long-term growth of 15–20% annually. » More on de.investing.com


  • Alphatec posts Q1 revenue and surgical volume gains, secures cheaper debt and issues 2026 guidance

    Alphatec reported Q1 2026 total revenue of $192 million, with surgical revenue up 17% and surgical case volume rising 21%; non-GAAP adjusted EBITDA reached $21 million and trailing twelve-month free cash flow was $7 million. The company secured a new bank facility that cuts annual interest expense by over $6 million and extends debt maturities to 2031, ending the quarter with $140 million in cash. For full-year 2026 Alphatec guides total revenue of about $882 million (≈15% growth), surgical revenue near $805 million, adjusted EBITDA around $134 million (15% of revenue) and at least $20 million in free cash flow. » More on finance.yahoo.com


  • Alphatec: strong growth in surgery business, EOS revenue falls short of expectations

    Alphatec reported total revenue of $192.1m for Q1 2026, missing analysts’ estimates; the stock fell sharply in after-hours trading. The surgery segment grew 17% to $178m, driven by higher case volumes and more surgeons, while the EOS imaging segment declined 18% to $14m. Despite improvements in revenue discipline, profitability rose significantly: adjusted EBITDA was $21m (margin 10.8%) and gross margin improved; EPS was $0.00. Alphatec refinanced debt on more favorable terms and reiterated its full-year guidance of $882m revenue and $134m adjusted EBITDA for 2026. » More on de.investing.com

Financials

In the last quarter, ALPHATEC HOLDINGS INC. had revenue of €187.08M and net profit of -€22.59M
(EUR) June 2026
YoY
Revenue 187.08M 18.84%
Gross profit 135.02M 23.27%
Net profit -22.59M 35.29%
EBITDA 5.66M 179.91%

Fundamentals

Metric Value
Market capitalization
€1.25B
Number of shares
153.79M
52-week high/low
€20.02 - €5.86
Dividends No
Beta
0.85
P/E ratio
-13.12
PEG ratio
-0.27
P/B ratio
-121.62
P/S ratio
1.78

Company profile

Alphatec Holdings, Inc. ist ein Medizintechnikunternehmen, das Technologien für die chirurgische Behandlung von Wirbelsäulenerkrankungen konzipiert, entwickelt und vorantreibt. Das Unternehmen bietet das SafeOp Neural InformatiX System an, eine Alpha InformatiX Produktplattform, die das Risiko intraoperativer Nervenverletzungen verringert; das Sigma transforaminale lumbale interkorporelle Fusion pedikelbasiertes Zugangssystem, das eine direkte Visualisierung anatomischer Orientierungspunkte ermöglicht; Sigma PTP Zugangs- und Patientenpositionierungssystem; Squadron lateraler Retraktor zur Maximierung der Patientenergebnisse; Invictus Spinal Fixation System, ein thorakolumbales Fixationssystem zur Behandlung einer Reihe von Pathologien; und Invictus MIS SingleStep System, das eine minimalinvasive Platzierung von Pedikelschrauben ermöglicht. Darüber hinaus bietet das Unternehmen das Invictus Modular Fixation System an, das die Anpassungsfähigkeit durch die Modularität der Schrauben erhöht; das OsseoScrew System zur Wiederherstellung der Integrität der Wirbelsäule; das Arsenal spinal fixation system, eine umfassende thorakolumbale Fixationsplattform zur Behandlung einer Reihe von degenerativen bis deformierenden Pathologien und chirurgischen Verfahren; Aspida Anteriores lumbales Plattensystem, ein Fixationssystem für die anteriore lumbale interkorporelle Fusion; AMP Anti-Migrationsplatte; OCT Wirbelsäulenfixationssystem; trestle luxe anteriores zervikales Plattensystem; und Insignia Anteriores zervikales Plattensystem. Darüber hinaus bietet das Unternehmen die Implantate IdentiTi Porous Ti, Transcend Lateral und Battalion Posterior Interbody Implants sowie Biologika bestehend aus Cervical Structural Allograft Spacers, 3D ProFuse Demineralized Bone Scaffold, Neocore Osteoconductive Matrix, Alphagraft Demineralized and Cellular Bone Matrix und Amnioshield Amniotic Tissue Barrier sowie EOS Imaging Products an. Das Unternehmen vertreibt seine Produkte über ein Netz unabhängiger Vertriebshändler und direkter Handelsvertreter in den Vereinigten Staaten. Das Unternehmen wurde 1990 gegründet und hat seinen Hauptsitz in Carlsbad, Kalifornien.

Name
ALPHATEC HOLDINGS INC.
CEO
Patrick S. Miles
Headquarters Carlsbad, ca
USA
Website
Sector
Consumer Discretionary
Industry
Household Durables
IPO
06/12/2006
Employees 913

Ticker symbols

Exchange Symbol
NASDAQ
ATEC
Frankfurt
L1Z1.F
Düsseldorf
L1Z1.DU
München
L1Z1.MU

Discover assets

Shareholders of ALPHATEC HOLDINGS INC. also invest in the following assets

🍪

Parqet  uses cookies. Learn more